TransTech Pharma Selects Genedata to Enhance High Throughput Screening Analysis
News Dec 14, 2005
Genedata has announced that TransTech Pharma has signed a multi-year license for high throughput screening analysis software Genedata Screener®.
Scientists at TransTech Pharma will use Screener to enhance their efforts to develop small molecules as therapeutics for treating human diseases.
"We sought a solution that could be deployed seamlessly with our drug discovery workflow," explained Dr. Robert Rothlein, Senior VP Biology at TransTech Pharma, Inc.
Screener has been integrated with TransTech Pharma’s IT and screening infrastructure. It will automate data quality evaluation and standardize the analysis of compound bioactivity.
Dr. Robert added, "Genedata’s solution saves time and cost in the lead discovery workflow."
"Screener’s modular design and open architecture were important factors in the success of our deployment at TransTech Pharma," says Dr. Michael Lindemann, Business Head Genedata Screener.
TransTech Pharma have developed a highly parallel and integrated Translational Technology® that links together drug design, synthesis and screening.
"We are able to support and enhance this workflow without resource-intensive customization of the Screener platform."
The ideal drug is one that only affects the exact cells and neurons it is designed to treat, without unwanted side effects. This concept is especially important when treating the delicate and complex human brain. Now, scientists have revealed a mechanism that could lead to this kind of long-sought specificity for treatments of strokes and seizures.READ MORE